First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

January 31, 2016

Study Completion Date

October 31, 2016

Conditions
Adenocarcinoma of Rectum
Interventions
DRUG

FOLFORINOX

INTRAVENOUS administration

Trial Locations (37)

68024

Colmar Ch, Colmar

Unknown

CHU, Amiens

CHU, Angers

CH, Avignon

CH, Beauvais

CHU, Besançon

CH, Béziers

Avicennes, Bobigny

CHU - Ht Lévêque, Bordeaux

Institut Bergonie, Bordeaux

CHU d'Estaing, Clermont-Ferrand

Centre G.F. Leclerc, Dijon

CHU, Dijon

Polyclinique, Francheville

CHD Vendée, La Roche-sur-Yon

Clinique Victor Hugo, Le Mans

CHRU - Hôpital Huriez, Lille

CHU La Timone, Marseille

Ipc - Cac, Marseille

CH Layne, Mont-de-Marsan

Centre Cahterine de Sienne, Nantes

Polyclinique le Languedoc, Narbonne

CH Georges Menon, Niort

CHR - Gasto, Orléans

AP - HP - Pitié Salpêtrière, Paris

CH, Pau

CH, Perpignan

CHU, Rouen

CH Le Foll, Saint-Brieuc

Clinique Armoricaine, Saint-Brieuc

Polyclinique Côte Basque Sud, Saint-Jean-de-Luz

CH Robert Morlevat, Semur-en-Auxois

CAC, Strasbourg

Polyclinique de l'Ormeau, Tarbes

Hôpitaux du Leman, Thonon-les-Bains

Clinique Saint Jean du Languedoc, Toulouse

CHRU Trousseau, Tours

All Listed Sponsors
lead

Federation Francophone de Cancerologie Digestive

OTHER

NCT01674309 - First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis | Biotech Hunter | Biotech Hunter